Tirzepatide Works For Weight Loss, But May Be Pricey; Questions Over Diabetes Drug’s Power Against Dementia
Read about the biggest pharmaceutical developments and pricing stories from the past week in KHN's Prescription Drug Watch roundup.
What To Know About The New Weight Loss Drug Tirzepatide. Will It Be Affordable?
An Eli Lilly drug if approved for weight loss could become the best-selling drug of all time, but concerns are mounting about who will actually be able to afford it. (Lovelace, Jr. 1/1)
Bay Area News Group:
Can Diabetes Drug Metformin Really Slow Aging, Reduce Dementia?
Metformin, a common medication to control diabetes, has become the controversial darling of tech’s health-conscious digerati who are enticed by preliminary research suggesting it might help promote longevity, reduce dementia and prevent a whole host of other conditions – including, most recently, long COVID. (Krieger, 1/3)
Unicycive's Pivotal Trial Of Takeda Kidney Drug Rival Hits Goal
Unicycive Therapeutics has laid the groundwork for entering a market targeted by Sanofi and Takeda, posting pivotal bioequivalence data on a candidate designed to improve compliance with kidney disease treatment regimens. (Taylor, 1/3)
The Boston Globe:
Drug Companies Set Sights On New COVID Medicines To Boost Depleted Arsenal
It was not that long ago that the medical community had a small arsenal of new drugs to prevent and treat COVID-19 in people most susceptible to severe disease. But the arrival of new variants, as well as the loss of two treatments for immunocompromised people, has amped up the urgency to develop a stronger generation of medicines. (Cross, 12/28)